Tracking cancer DNA in blood to detect early return of breast cancer
Part of Cancer, Skin clinical trials.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with breast cancer.
- You must be willing to give blood or tissue samples for research.
- Depending on your situation, you should be in one of these stages: newly diagnosed before surgery, or after surgery with no signs of cancer, or more than 5 years since diagnosis with no signs of cancer.
- If your cancer is HR+, HER2-, it must be considered high risk (like having at least 4 positive lymph nodes, or 1-3 positive nodes with a large tumor or high grade).
- You cannot have another active cancer, or have had a different cancer (except non-invasive breast changes) within the last 3 years.
- Your treatment must be aimed at curing the cancer (not just managing it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.